About Inflammatix
Inflammatix is a molecular diagnostics company that has developed a first-in-class approach to diagnosing acute infections and sepsis by 'reading' the immune system's response rather than targeting pathogens directly. The company's flagship product, TriVerity, is an FDA-cleared diagnostic test designed for emergency department use that provides three actionable scores: likelihood of bacterial infection, likelihood of viral infection, and all-cause illness severity (defined as risk of progression to mechanical ventilation, vasopressors, or renal replacement therapy within seven days). The company's technology is powered by measuring mRNA profiles from immune cells in whole blood, combined with machine learning and artificial intelligence to interpret these host response signatures. This approach addresses a critical limitation of traditional pathogen-targeting tests, which are often insensitive because most infections remain locally contained and don't penetrate the bloodstream. Inflammatix's immune cells circulate into the blood after fighting infections locally, allowing their signatures to be measured and analyzed. Inflammatix leverages expertise in bioinformatics, molecular biology, and machine learning to develop diagnostics that help physicians make confident and timely clinical decisions in emergency settings where time, space, and certainty are in short supply. The company's mission centers on empowering emergency clinicians to rapidly recognize and act early on acute infections with unparalleled precision, transforming triage through early actionability, prognostic clarity, and exceptional accuracy that has been clinically proven to exceed standard of care.
Mission & Story
Mission
Empowering emergency clinicians to rapidly recognize and act early on acute infections with unparalleled precision
Founding Story
Co-founded by Tim Sweeney, MD, PhD, who serves as CEO. The founding story emphasizes leveraging millions of years of immune system evolution to develop targeted diagnostic responses.
Clinical Focus
Medical conditions and clinical areas addressed by Inflammatix.
Who It Serves
Milestones & Awards
Recent Milestones
FDA clearance received for first-in-class TriVerity Test
Awards & Recognition
First-in-class FDA clearance for TriVerity Test
Social & Media
Latest Updates
Sepsis Moves Fast: A New Test Moves Faster
AnMed First in SC to Provide Innovative TriVerity Diagnostic
ICU Care Transformed: Precision Medicine Reaches Sepsis and Critical Illness
Inflammatix Collaborates with University of Nebraska Medical Center to Support Rapid Response to the Hantavirus Outbreak Using TriVerity®
Transforming sepsis care with Purvesh Khatri: How a winding path led to a life-saving test (podcast)
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.